tldrdailynews.com logo

FDA advisors question effectiveness of Biogen's ALS drug for rare form of the disease

1 min read
Source: CNBC
FDA advisors question effectiveness of Biogen's ALS drug for rare form of the disease
Photo: CNBC
TL;DR

The FDA's independent panel of advisors voted against the effectiveness of Biogen's investigational ALS drug, Tofersen, for a rare and aggressive form of the disease. The drug failed to meet the primary and secondary endpoint in a phase three clinical trial, but the panel voted unanimously that the drug could have a clinical benefit in reducing a protein associated with disease severity. The FDA will make a final decision on April 25, and if approved, Biogen will study the drug further to verify its clinical benefits.

Topics:businesshealth#als#biogen#clinical-trials#fda#health#tofersen
Share this article
  1. FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease  CNBC
  2. Biogen ALS drug considered not effective by FDA advisory panel  MarketWatch
  3. FDA advisory panel recommends conditional approval of Biogen's drug for rare form of ALS  STAT
  4. FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease  CNBC
  5. Biogen ALS drug tofersen earns mixed voting by FDA advisors  Seeking Alpha

Want the full story? Read the original reporting

Read on CNBC